

Prevalence and seroprevalence of COVID-19 infection among older people: A scoping review based on population-based studies in 2020-2022

Jingxin Lei^{1,*}, Phymar Soe¹

1. School of Population and Public Health, University of British Columbia, BC V6T 1Z4, Canada

*: Corresponding author at: School of Population and Public Health, University of British Columbia, BC V6T 1Z4, Canada

Abstract

Background

Accurate estimates of the prevalence of infections play an important role in COVID-19 surveillance. Older people are known to have higher risks of severe outcomes after infection, but whether they also have a higher infection rate remains unclear. To obtain estimates of COVID-19 prevalence among older people, we synthesized evidence from RT-PCR-based prevalence and serological studies.

Methods

We conducted a scoping review using a comprehensive search of MEDLINE (Ovid), Embase (Ovid), Europe PMC, ClinicalTrials.gov, and the WHO COVID-19 Research Database from December 2019 to Oct 2022. We included population-based cross-sectional (sero)prevalence studies among older people (i.e., people aged ≥ 65 +/- 5 years) who were tested for SARS-CoV-2 infection using RT-PCR tests, antigen tests, or serological tests. Studies that were conducted solely in institutional housing were excluded. Eligible studies were extracted and critically appraised. We described and mapped the prevalence (tested by RT-PCR or antigen tests) and seroprevalence (tested by serological tests) by geographical area and time. We then compared the estimated prevalence with WHO-reported prevalence and the prevalence among younger age groups from the same study.

Results

We identified 202 (sero)prevalence estimates from 126 studies, covering 50 countries up to October 2022. Of the 126 studies, 28 studies estimated RT-PCR-based prevalence; 104 studies estimated seroprevalence, ranging from 0% in Jordan to 22.5% in the United States in 2020, from 0.41% in Brazil to 98% in Chile in 2021. In the year 2020, prevalence of COVID-19 ranged from 0.0006% in China, to 52.8% in Brazil, while in 2021, prevalence ranged from 0.06% in England to 41.1% in Brazil. The ratio of the reported prevalence to estimated prevalence ranged from <0.01 to 77.50, where 86% (24/28) studies estimated a

higher prevalence than WHO reported and half of them estimated >10 times higher prevalence. One third of studies (32%, 9/28) estimated a higher prevalence in older people compared with younger people.

Conclusions

Our findings suggest that underreporting of COVID-19 cases among older people may exist extensively worldwide. Compared with younger groups, older people were less likely to be infected with COVID-19 in two thirds of the studies through the first two years of the pandemic.

Keywords

COVID-19, older adults, prevalence, PCR, serological tests, underreporting

Background

The COVID-19 pandemic is one of the most distributed pandemics in human history¹. As of March 10, 2023, 676,609,955 cases and 6,881,955 deaths have been reported². However, the reported cases may not capture the actual burden of the pandemic, partially due to limited test availability and accessibility^{3,4}, asymptomatic infections⁵, and the extensive allocation of self-test kits⁶. For instance, according to a global survey covering respondents from Africa, Americas, Eastern Mediterranean, Europe, Southeast Asia, and Western Pacific, self-testing were available in 101 out of 139 countries in early 2022⁷.

COVID-19 seroprevalence and prevalence studies across the world have described the spread of the virus over time and in different regions, age-groups and socioeconomic profiles. Prevalence studies estimate prevalence of SARS-CoV-2 virus RNA (based on nucleic acid amplification tests, or NAAT in short) or antigen of SARS-CoV-2 (antigen based). Reverse transcription polymerase chain reaction (RT-PCR) is the most widely used method among NAATs. It is one of the most accurate tests of active infections but more expensive and time-consuming than antigen tests, which are more accessible alternatives but less accurate. Seroprevalence studies estimate prevalence of SARS-CoV-2 antibodies as a result of vaccination or infection, depending on the types of antibodies. Antibody remains detectable months after infection or vaccination⁸. Compared with RT-PCR tests, both antibody and antigen tests can be conducted quicker and cheaper, thus are more commonly used. Because of their ability to detect past infection or vaccination weeks or months ago, antibody tests have been used to estimate COVID-19 prevalence, as well as to estimate the extent of case underreporting^{9,10}. However, based on WHO's definition¹¹, a confirmed case is either an individual with a positive NAAT result or a suspect case, based on clinical and/or epidemiological criteria, with a positive antigen result. Literature suggested that antibody tests tend to provide a higher positivity rate than PCR tests¹². Using a seroprevalence-based estimate of prevalence may lead to a higher estimate of COVID-19 infections. No review has analyzed PCR-based prevalence studies at the initiation of this study.

Older people are among the most vulnerable populations to experience severe outcomes after COVID-19 infection¹³⁻¹⁵. However, whether older people are also more vulnerable to COVID-19 infection itself remains unclear. Since a recent review from Bergeri et al has analyzed seroprevalence studies comprehensively¹⁰, in this review we aim to 1) describe COVID-19 seroprevalence and prevalence among older people across region and time, 2) assess the extent of underestimation of COVID-19 infections based on prevalence studies, and 3) compare the prevalence between older people and younger groups.

Methods

Information sources and search strategy

We searched the following electronic databases: MEDLINE (Ovid), Embase (Ovid), and Europe PMC from December 2019 to Oct 19, 2022. Embase and Europe PMC were searched to include preprints. We also searched ClinicalTrials.gov and the WHO COVID-19 Research Database to include COVID-19 prevalence studies registered in these databases. Backward and forward citation searching on included studies was conducted. The comprehensive search strategies with MeSH terms are summarized in Table 1. For database where MeSH terms were not available, following keywords are searched: (“COVID-19” or “SARS-CoV-2” or “coronavirus”) and (“prevalence” or “incidence” or “seroprevalence”) and (“covid-19 testing” or “nucleic acid test” or “antigen test” or “rapid test” or “antibody” or “PCR” or “RT-PCR” or “polymerase chain reaction”) and (“older people” or “older adult” or “aged people”). The review protocol¹⁶ is registered on Open Science Framework¹⁷(Registration DOI: doi.org/10.17605/OSF.IO/37RZS).

Eligibility criteria

This review included cross - sectional or repeated cross - sectional studies using molecular tests, antigen tests, or serological tests (i.e., antibody tests) to estimate the prevalence and seroprevalence of COVID-19

of people in municipalities, regions, states, or countries around the world. Studies were excluded if the study:

- (i) was not a cross-sectional study,
- (ii) did not report prevalence or seroprevalence specifically among the older population,
- (iii) restricted to a specific group of participants only (e.g., people living in residential facilities such as long-term care facilities or nursing homes, or having certain underlying condition such as cardiovascular diseases), and
- (iv) had a sample size less than 100

For the purpose of our review, older populations were defined as people with a minimum age of 65 ± 5 years. Studies using convenience sampling were also included to gather information as thorough as possible. Only literature with a title and abstract written in English were included. Because of the rapidly evolving state of the COVID-19 pandemic, non-peer-reviewed articles such as pre-prints and scientific reports were included. Conference proceedings alone were excluded.

Study selection and data extraction

All reference management were performed in Covidence¹⁸. After the removal of duplicates, titles and abstracts of all search results were assessed for inclusion against our eligibility criteria. Prior to the screening of title and abstract, the screening form was calibrated through pilot testing¹⁹ with a random sample of 25 records from the literature search by two independent reviewers. At the first stage, two reviewers JL and PS screened all titles and abstracts independently to decide if the record was potentially eligible, irrelevant, or of indeterminate relevance. All potentially eligible records and those of indeterminate relevance were retrieved and screened at the full-text level. Discrepancies were resolved by discussion and consensus between the two reviewers or by a third-party decision. Information of the included studies was extracted according to a pre-specified data extraction form (Table 2). Prevalence of younger age group from the same study was also extracted if available. We did not extract vaccination

status as most of the studies didn't report it. Two reviewers extracted data independently and consensus was reached afterwards.

Statistical analyses

A narrative description of the prevalence and seroprevalence studies was presented by geographical region and time. For prevalence studies, we compared the prevalence of COVID-19 based on included studies with reported prevalence in the same country. The reported prevalence was calculated by the reported cases among people aged 65 and above during the sample collection period reported by WHO²³, divided by total population size aged 65 and above in 2021, reported by United Nations, World Population Prospects²⁴. If age-specific cases were not available in a country, we would use all-age prevalence at the same time as a comparator. Analyses were conducted with R language²⁵.

Results

Eligible evaluations

6,248 records were identified in the databases after the comprehensive search as of October 19, 2022. After automatically removing the duplicates by Covidence, 5,163 records were screened. 4,958 records were excluded in the title and abstract screening; and 205 records retrieved for full text. Fifty-nine articles were excluded in the full-text screening due to off-target population (n=29), off-target measurement (n=15), inadequate sample size (n=8), or duplicates (n=7). In total, 126 unique studies were retrieved in 146 records (Figure 1). In these 126 studies, 202 estimates of (sero-)prevalence were extracted. The information extracted for the eligible studies is summarized in Supplementary Table.

General description of the studies

Of the 126 included studies, samples of 85 studies were collected in 2020, 11 were collected in 2021, 1 was collected in 2022, and 29 were collected in multiple rounds across 2020-2022. The prevalence and seroprevalence estimates over time are shown in Figure 2. Five studies were preprints or scientific reports,

while the majority (n=121) of studies were peer-reviewed journal articles. Regions with the most studies were Europe (n=48), North America (n=30), and Asia (n=28). Only 7 studies were conducted in Africa and 13 studies in South America (Figure 3 and 4). No identified studies were conducted in Oceania. Countries with most studies are the United States (26 unique studies with 39 estimates), India (11 unique studies with 19 estimates), and Brazil (8 unique studies with 13 estimates). Ninety studies were prospective cross-sectional studies, 34 studies were retrospective cross-sectional studies, and 2 studies collected seroprevalence prospectively whereas the reported PCR-based prevalence data was retrieved retrospectively from other sources. Half (n=66, 52%) of the studies were randomly sampled from the general population. For non-randomly sampled studies, 15 studies were sampled from the general population, 14 studies were based on samples for COVID-19 testing, and 26 studies were based on samples for other reasons (e.g., routine laboratory tests). Three studies had a different sample scheme for prevalence and seroprevalence²⁶⁻²⁸, and one study reported in three publications sampling from the general population randomly in Russia²⁹ but non-randomly in the Kyrgyz Republic³⁰ and the Republic of Belarus³¹. The age ranges for older participants were defined as 60 years and above (n=69 studies), 65 and above (n=46 studies), and 70 and above (n=7 studies).

Nineteen studies measured prevalence of COVID-19 only, 95 studies measured seroprevalence (i.e., antibody level) only, and 9 studies measured both prevalence and seroprevalence. Three studies³²⁻³⁴ used a mixture of PCR, antibody, and/or self-reported COVID-19 history. For the 28 studies reporting COVID-19 prevalence, 26 studies were based on RT-PCR tests (on swab or blood samples, or both), one study was based on an antigen test³⁵, and one study was based on both antigen and RT-PCR tests³⁶. For studies of seroprevalence, most studies used testing methods targeting on either IgA, IgM, or IgG. Two studies used anti-RBD antibodies^{37,38}, and two studies changed targeting antibody in the middle of the sample collection^{34,39}.

Prevalence studies and comparison with younger age group and WHO reports

In total, 28 studies in 16 countries reported estimates of prevalence, either based on RT-PCR or antigen tests. All studies were conducted in 2020 or 2021, except for REACT-1 where the most recent round published was conducted in February and March 2022⁴⁰. The prevalence of COVID-19 ranged diversely, from 0.006%⁴¹ in China to 52.8%⁴² in Brazil in 2020, and from 0.04%⁴³ in the UK to 41.1%⁴⁴ in Brazil in 2021. Study 30^{40,43,45-47} and Study 89⁴⁸ had multiple rounds of sample collection. For Study 30 in England, the prevalence measurement started from May 2020, decreased in July – September 2020, increased thereafter until January 2022, and decreased in the latest round available in March 2022 (round 18). For Study 89 in South Africa, four rounds of sample collection were conducted monthly from March 2020. Prevalence decreased in April and May 2020 and increased dramatically (from 1.8% to 15%) in June 2020.

The comparison with prevalence in younger age groups is represented in Table 3 and Figure 5. 32% studies (9/28, 12/42 estimates) found a higher infection prevalence among older people compared with younger people. Four studies estimated significantly higher prevalence among the older people, while 6 studies estimated significantly lower prevalence.

The comparison between study-based estimates and WHO-reported estimates are as shown in Table 3 and Figure 5. For seven of the included prevalence studies^{27,48-53} (marked with * in Table 3), WHO reported daily cumulative COVID-19 cases were not available when stratified by age group, thus all-ages prevalence was used as a comparator. Out of the 28 studies, 4 studies from England^{40,43,45-47}, United States^{54,55}, and Hungary⁵⁶ reported a lower prevalence compared to the reported estimates (ratio of study-based estimates versus WHO reported estimates: 1.02 - 77.5). Twenty-three studies reported higher prevalence compared to the WHO reported estimates (ratio: <0.01 ~ 0.53), and 14 studies (50%) reported at least ten times higher prevalence compared to WHO figures.

Seroprevalence studies

In total, 104 studies reported estimates of seroprevalence. Twenty-seven studies were national studies whereas 66 studies were regional or sub-national studies. In 2020, seroprevalence was estimated ranging from 0% in Jordan⁵⁷ to 22.5% in United States⁵⁸, from 0.41% in Brazil⁵⁹ to 98% in Chile⁶⁰ in 2021.

Twenty-five studies reported multiple rounds of sample collection. The temporal trend of COVID-19 seroprevalence for 23 of the studies is shown in Figure 2. Two studies^{61,62} were excluded as they only reported adjusted estimates for subgroups.

Discussion

This review covers prevalence estimates from 50 countries or regions from January 2020 to March 2022, but prevalence in these areas only represent a small part of the COVID-19 infection and vaccination among older adults in the world. Along with other reviews^{63,64}, this scoping review shows that prevalence and seroprevalence studies were concentrated in several high-resource countries or areas such as the United States and Europe. Although our search included most of 2022, most included studies were conducted in 2020 and 2021; this may have reflected an urgent need to obtain prevalence estimates early on in the pandemic as well as the time it takes for the publishing process.

Twelve out of 42 estimates of prevalence were higher in older people, which indicates that the older adults were more likely to get infected in these areas. For the rest (30/42 estimates), a lower prevalence among older adults was observed comparing with younger groups in these regions during the sample collection time. Other primary studies and literature reviews also show a divergent age effect on infection. Zhang et al⁶⁵ found that the infection rate was higher in older adults than people aged 15 to 64 years in February 2020 while Romain et al⁶⁶ found a higher prevalence among adolescents in summer 2020. Bergeri et al¹⁰ found a lower prevalence among people aged 0 to 9 years 10 to 19, and 60 and above across 2020-2022, comparing with young adults aged 20 to 29 years. A modeling study in Brazil⁶⁷ showed little age effect in the difference of infection risks between regions. Nevertheless, studies have been

agreed upon older age being a risk factor of worse outcomes of COVID-19 infection, including severe symptoms, hospitalization, and mortality¹³⁻¹⁵. Policies and measurements have been advocated and implemented to protect older people⁶⁸ across the pandemic, however, the efficiency remains concerning in some countries.

Regardless of the age group, we found universal discrepancies between study-based prevalence and WHO reported prevalence where most of the studies reported a much higher prevalence. Besides underreporting, alternative reasons such as nonrepresentative population selection, lack of adjustment for test performance and study design, and delay of case reporting, may also lead to the difference. For example, participants in Study 104⁴¹ were individuals who were tested for COVID-19 in Zhongnan hospital of Wuhan University, and tests were only available for people with symptoms⁶⁹, which may cause the prevalence in the study population to be significantly higher than the prevalence among general population. Nevertheless, infections estimated based on seroprevalence were consistently found to exceed the reported cases globally^{9,10,70-72}. Monitoring current infection rate helps scientists and the public to monitor the spread of the disease and to prevent health services shortage due to outbreaks. Therefore, inaccurate estimation of the prevalence can be misleading to decision makers and the allocation of health services.

Our review also calls for attention on the importance of reporting participants' age distribution in COVID-19 studies. Comparing with previous reviews^{9,10}, fewer studies were included in our review due to lack of age information. This can also be seen from Bergeri et al's review¹⁰ and Bobrovitz et al's review⁹ where only 23% (117/513) and 21% (127/605) of the studies reported seroprevalence of the older adults.

This scoping review focuses on presenting prevalence and seroprevalence of COVID-19 among the older adults. However, this review does have limitations. This review only searched for English-language studies until October 2022, which may omit important and the most recent materials. Seventy-six studies had age thresholds different from the WHO threshold of 65 years (mostly 60 years), which may lead to

biased estimates of the ratio between WHO-reported and study-based prevalence. For seven of the included prevalence studies, WHO-reported daily cumulative COVID-19 cases were not available when stratified by age group for comparison. Thus, for these studies we could not directly compare the study-based and reported prevalence for older people.

Conclusions

The prevalence and seroprevalence of COVID-19 have been crucial indicators of COVID-19 management. This review describes these two indicators among one of the most vulnerable populations, the older adults. Prevalence of COVID-19 ranges from 0.0006% in 2020 in a Chinese study to 52.8% in mid 2020 in a Brazilian study, and seroprevalence ranges from 0 in August 2020 in a Jordan study to 98% in late 2021 in a Chile study. Prevalence among the older adults were higher in one third of the studies compared with the younger group, but in most countries, both far exceeded WHO reported prevalence.

Table 1 Comprehensive search strategy

		MEDLINE ¹	Embase
1	COVID-19/	192270	121814
2	SARS-CoV-2/	139231	38177
3	(covid* or coronavirus or corona virus or sars-cov-2 or pandemic).mp. [mp=title, book title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]	348147	419612
4	1 or 2 or 3	348147	419612
5	prevalence/	335697	879533
6	incidence/	296161	525645
7	seroprevalence.mp. or Seroepidemiologic Studies/	35437	39569
8	prevalence.mp.	840829	1290274
9	5 or 6 or 7 or 8 [prevalence/seroprevalence]	1111206	1755607
10	covid-19 testing/ or covid-19 nucleic acid testing/	9030	6920
11	(nucleic acid test* or antigen test* or rapid test*).mp.	16272	33779
12	(estimat* or underreport*).mp.	1371317	1745061
13	10 or 11 or 12 [testing]	1392591	1780575
14	exp aged/ or exp geriatrics/ or exp geriatric psychiatry/ or exp geriatric nursing/ or exp *geriatric psychiatry/ or exp *dental care for aged/ or exp *health services for the aged/ or (elder* or eldest or frail* or geriatri* or old age* or oldest old* or senior* or senium or very old* or septuagenarian* or octagenarian* or octogenarian* or nonagenarian* or centarian* or centenarian* or supercentenarian* or older people or older subject* or older patient* or older age* or older adult* or older man or older men or older male* or older woman or older women or older female* or older population* or older person*).ti,ab,kf.	3668977	3904096
15	cross-sectional studies.mp.	451139	18593
16	mass screening/ or anonymous testing/	115098	60437
17	9 or 15 or 16 [upated prevalence/seroprevalence]	1518900	1817065
18	Serologic Tests/ or Serologic Tests.mp.	24427	88223
19	Serology.mp. or Serology/	29341	106912
20	immunoassay/ or fluoroimmunoassay/ or immunoenzyme techniques/ or immunologic tests/	108361	4572948
21	Antibodies/ or antibod*.mp.	1256738	1600218
22	18 or 19 or 20 or 21 [serologic testing]	1343971	5143721
23	polymerase chain reaction/ or real-time polymerase chain reaction/ or reverse transcriptase polymerase chain reaction/ or pcr.mp. or polymerase chain reaction.mp.	930022	1425171
24	13 or 23 [nucleic acid testing]	2282195	3147498
25	22 or 24 [all testing methods]	3495859	7567506
26	4 and 17 and 25	10592	20739

27	14 and 26	2224	4451
28	limit 27 to (english language and yr="2019 -Current")	1820	3985

Note: 1. MEDLINE version: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-

Indexed Citations, Daily and Versions(R) 1946 to September 04, 2020

Table 2 Data extraction form

Leading author
Publication year and month
Title
Article type
Country and region
Area type (City, town, rural or all)
Study design (prospective or retrospective)
Study population
Inclusion and exclusion criteria
Sample size
Sampling method
Time of sample collection
Age range
Prevalence or seroprevalence
Testing methods
Adjusting methods

Table 3 Comparison between study-based estimates and surveillance-based estimates

ID	Country	Estimates % (A)	WHO Reported % (B)	Ratio (B/A)	Younger group % (C)	Ratio (C/A)
2	Qatar	19.8 (19.2, 20.4)	1.65	0.13	28.3 (28.2, 28.4)	1.33
2	Qatar	12.8 (11.9, 13.8)	2.13	0.11	17.0 (16.7, 17.2)	1.43
5	Mali*	14.7 (8.7, 23.4)	0.03	<0.01	9.9 (7.9, 12.3)	0.67
6	USA	12.3 (11.8, 12.8)	1.81	0.15	11.4 (11.3, 11.5)	0.93
25	Italy	11.5 (10.9, 12.1)	0.34	0.03	12.3 (11.6, 13.1)	1.07
30	England	0.07 (0.05, 0.12)	0.65	9.33	0.15 (0.12, 0.17)	2.14
30	England	0.06 (0.04, 0.09)	0.79	13.15	0.08 (0.07, 0.10)	1.33
30	England	0.04 (0.02, 0.06)	0.82	20.48	0.03 (0.02, 0.04)	0.75
30	England	0.04 (0.03, 0.07)	0.85	21.28	0.11 (0.09, 0.13)	2.75
30	England	0.06 (0.04, 0.1)	4.65	77.50	0.15 (0.12, 0.18)	2.50
30	England	0.22 (0.18, 0.29)	4.80	21.81	0.66 (0.60, 0.73)	3.00
30	England	0.38 (0.31, 0.45)	6.04	15.90	0.92 (0.85, 0.99)	2.42
30	England	0.75 (0.66, 0.86)	6.98	9.31	1.7 (1.6, 1.8)	2.27
30	England	0.40 (0.33, 0.48)	7.71	19.27	1.6 (1.5, 1.7)	4.00
30	England	2.8 (2.6, 3.0)	10.30	3.68	4.5 (4.3, 4.6)	2.14
30	England	2.1 (1.9, 2.3)	12.05	5.74	3.1 (3.0, 3.2)	1.11
31	USA	1.4 (0.4, 4.5)	0.42	0.30	3.2 (2.6, 4.0)	2.29
32	USA	0.4 (0.0, 2.5)	0.55	1.39	1.9 (1.1, 3.2)	4.75
34	South Korea*	3.0 (2.8, 3.1)	0.01	<0.01	3.5 (3.4, 3.6)	1.17
36	Brazil	41.1 (33.5, 49.1)	3.29	0.08	38.2 (34.1, 42.4)	0.93
38	UK	17.9 (15.9, 20.1)	0.11	0.01	14.1 (12.8, 15.6)	0.79
40	USA	1.6 (1.2, 2.2)	0.56	0.35	5.9 (5.3, 6.6)	3.69
42	England	0.9 (0.0, 5.8)	0.17	0.18	2.4 (1.4, 3.9)	2.67
45	Cameroon*	17.3 (14.8, 20.1)	0.05	<0.01	12.6 (12.0, 13.2)	0.73
50	USA	1.2 (0.3, 4.5)	1.45	1.21	2.2 (1.2, 4.0)	1.83
52	Canada	12.1 (11.8, 12.4)	0.11	0.01	5.5 (5.3, 5.7)	0.45
58	Sri Lanka*	7.4 (6.3, 8.7)	0.25	0.03	18.2 (17.6, 18.9)	2.46
69	India*	6.1 (5.9, 6.3)	0.29	0.05	3.3 (3.2, 3.3)	0.54
75	USA	0.9 (0.4, 1.5)	0.42	0.46	1.9 (1.4, 2.6)	2.11
76	Hungary	0.06 (0.0, 0.16)	0.06	1.02	0.63 (0.47, 0.84)	10.50
78	USA	8.3 (8.3, 8.4)	2.12	0.26	10.1 (10.1, 10.1)	1.22
83	USA	7.5 (7.3, 7.7)	0.58	0.08	13.2 (13.1, 13.4)	1.76
89	South Africa*	5.5 (4.3, 7.1)	0.001	<0.01	5.6 (5.2, 6.2)	1.02
89	South Africa*	2.1 (1.5, 2.9)	0.01	<0.01	2.2 (2.0, 2.6)	1.05
89	South Africa*	1.8 (1.5, 2.2)	0.03	0.02	3.6 (3.4, 3.8)	2.00
89	South Africa*	15.0 (14.3, 15.7)	0.15	0.01	18.7 (18.5, 19.0)	1.25
98	Ecuador	14.5 (12.0, 17.3)	1.73	0.12	16.3 (15.0, 17.6)	1.12
104	China	0.0006 (0.0000, 0.0040)	0.000008	0.01	0.05 (0.03, 0.10)	83.33

105	India *	7.7 (7.4, 8.0)	1.19	0.15	Not reported	-
112	Canada	11.4 (11.2, 11.7)	0.20	0.02	10.9 (10.7, 11.1)	0.96
114	Poland	7.2 (6.8, 7.6)	3.84	0.53	13.5 (13.1, 13.9)	1.88
123	Brazil	52.8 (52.2, 53.5)	0.95	0.02	41.6 (41.2, 41.9)	0.79

Note: Age-specific cases were not available from WHO in countries with *, so all-age prevalence was calculated instead.




Figure 1 PRISMA Flow Diagram




Figure 2 Estimated prevalence (left) and seroprevalence (right) by month, sampling, and testing methods




Figure 3 Map of COVID-19 prevalence in a global view




Figure 4 Map of COVID-19 seroprevalence in a global view




Figure 5 Comparison between study-based estimates and surveillance-based estimates

References

1. Feehan J, Apostolopoulos V. Is COVID-19 the worst pandemic? *Maturitas*. 2021;149:56.
doi:10.1016/J.MATURITAS.2021.02.001
2. COVID-19 Map - Johns Hopkins Coronavirus Resource Center. Accessed September 18, 2022.
<https://coronavirus.jhu.edu/map.html>
3. Supply Shortages Impacting COVID-19 and Non-COVID Testing. Accessed August 10, 2023.
<https://asm.org/Articles/2020/September/Clinical-Microbiology-Supply-Shortage-Collecti-1>
4. Lieberman-Cribbin W, Tuminello S, Flores RM, Taioli E. Disparities in COVID-19 Testing and Positivity in New York City. *Am J Prev Med*. 2020;59(3):326.
doi:10.1016/J.AMEPRE.2020.06.005
5. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLoS Med*. 2020;17(9). doi:10.1371/JOURNAL.PMED.1003346
6. Ritchey MD, Rosenblum HG, Del Guercio K, et al. COVID-19 Self-Test Data: Challenges and Opportunities — United States, October 31, 2021–June 11, 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(32):1005-1010. doi:10.15585/MMWR.MM7132A1
7. Sakala M, Johnson C, Chirombo J, Sacks JA, Baggaley R, Divala T. COVID-19 self-testing: Countries accelerating policies ahead of WHO guidelines during pandemics: A Global Survey. *medRxiv*. Published online August 24, 2023:2023.08.23.23294474.
doi:10.1101/2023.08.23.23294474
8. Baraniuk C. How long does covid-19 immunity last? *BMJ*. 2021;373. doi:10.1136/BMJ.N1605

9. Bobrovitz N, Arora RK, Cao C, et al. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. *PLoS One*. 2021;16(6).
doi:10.1371/JOURNAL.PONE.0252617
10. Bergeri I, Whelan MG, Ware H, et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. *PLoS Med*. 2022;19(11). doi:10.1371/JOURNAL.PMED.1004107
11. WHO COVID-19 Case definition. Accessed October 19, 2023.
https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2022.1
12. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature Medicine* 2020 26:6. 2020;26(6):845-848. doi:10.1038/s41591-020-0897-1
13. Mueller AL, Mcnamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? *Aging (Albany NY)*. 2020;12(10):9959. doi:10.18632/AGING.103344
14. Singhal S, Kumar P, Singh S, Saha S, Dey AB. Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis. *BMC Geriatr*. 2021;21(1):1-9.
doi:10.1186/S12877-021-02261-3/TABLES/3
15. Cohen K, Ren S, Heath K, et al. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. *BMJ*. 2022;376. doi:10.1136/BMJ-2021-068414
16. Lei J. Prevalence and seroprevalence of COVID-19 infection among the elderly people based on population-based surveys in 2020-2022: A scoping review protocol. Published online 2022:17.
doi:none
17. OSF. Accessed October 20, 2022. <https://osf.io/>

18. Covidence - Better systematic review management. Accessed October 20, 2022.
<https://www.covidence.org/>
19. Jordan Z, Lockwood C, Munn Z, Aromataris E. The updated Joanna Briggs Institute Model of Evidence-Based Healthcare. *Int J Evid Based Healthc*. 2019;17(1):58-71.
doi:10.1097/XEB.0000000000000155
20. Bobrovitz N, Noël K, Li Z, et al. SeroTracker-RoB: a decision rule-based algorithm for reproducible risk of bias assessment of seroprevalence studies. *medRxiv*. Published online November 16, 2022:2021.11.17.21266471. doi:10.1101/2021.11.17.21266471
21. Migliavaca CB, Stein C, Colpani V, Munn Z, Falavigna M. Quality assessment of prevalence studies: a systematic review. *J Clin Epidemiol*. 2020;127:59-68.
doi:10.1016/j.jclinepi.2020.06.039
22. Borges Migliavaca C, Stein C, Colpani V, Barker TH, Munn Z, Falavigna M. How are systematic reviews of prevalence conducted? A methodological study. *BMC Med Res Methodol*. 2020;20(1):1-9. doi:10.1186/S12874-020-00975-3/TABLES/2
23. Detailed Surveillance Data Dashboard. Accessed August 22, 2023. <https://covid19.who.int/more-resources>
24. World Population Prospects - Population Division - United Nations. Accessed August 22, 2023.
<https://population.un.org/wpp/>
25. R: The R Project for Statistical Computing. Accessed May 10, 2022. <https://www.r-project.org/>
26. Dixon BE, Wools-Kaloustian K, Fadel WF, et al. Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: Results from a statewide epidemiological study. *medRxiv*. Published online October 22, 2020.
doi:10.1101/2020.10.11.20210922

27. Laxminarayan R, B CM, G VT, Arjun Kumar K V., Wahl B, Lewnard JA. SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study. *Lancet Infect Dis.* 2021;21(12):1665-1676. doi:10.1016/S1473-3099(21)00393-5
28. Parker DM, Bruckner T, Vieira VM, et al. Predictors of Test Positivity, Mortality, and Seropositivity during the Early Coronavirus Disease Epidemic, Orange County, California, USA. *Emerg Infect Dis.* 2021;27(10):2604. doi:10.3201/EID2710.210103
29. Popova AY, Smirnov VS, Andreeva EE, et al. Sars-cov-2 seroprevalence structure of the russian population during the covid-19 pandemic. *Viruses.* 2021;13(8). doi:10.3390/V13081648/S1
30. Popova AY, Kasymov OT, Smolenski VY, et al. SARS-CoV-2 herd immunity of the Kyrgyz population in 2021. *Med Microbiol Immunol.* 2022;211(4):195-210. doi:10.1007/S00430-022-00744-7/FIGURES/7
31. Popova AY, Tarasenko AA, Smolenskiy VY, et al. Herd immunity to SARS-CoV-2 among the population of the Republic of Belarus amid the COVID-19 pandemic. *Russian Journal of Infection and Immunity.* 2021;11(5):887-904. doi:10.15789/2220-7619-HIT-1798
32. Goss CW, Maricque BB, Anwuri V V., et al. SARS-CoV-2 active infection prevalence and seroprevalence in the adult population of St. Louis County. *Ann Epidemiol.* 2022;71:31. doi:10.1016/J.ANNEPIDEM.2022.03.002
33. Martín-sánchez V, Fernández-villa T, Carvajal Urueña A, et al. Role of Rapid Antigen Testing in Population-Based SARS-CoV-2 Screening. *J Clin Med.* 2021;10(17):3854. doi:10.3390/JCM10173854

34. Whitaker H, Tsang RSM, Button E, et al. Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network. *J Infect.* 2022;84(6):814. doi:10.1016/J.JINF.2022.04.016
35. da Silva Torres MK, Lopes FT, de Lima ACR, et al. Seroprevalence and risk factors for COVID-19 in the metropolis of the Brazilian Amazon. *Sci Rep.* 2022;12(1). doi:10.1038/S41598-022-12629-Z
36. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. *Scientific Reports 2021 11:1.* 2021;11(1):1-15. doi:10.1038/s41598-021-85428-7
37. Mustanski B, Saber R, Ryan DT, et al. Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago. *Ann Epidemiol.* 2022;66:44. doi:10.1016/J.ANNEPIDEM.2021.10.006
38. Sood N, Pernet O, Lam CN, et al. Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study. *JAMA Netw Open.* 2022;5(1):e2144258-e2144258. doi:10.1001/JAMANETWORKOPEN.2021.44258
39. Berselli N, Filippini T, Paduano S, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy population before the COVID-19 second wave. *Int J Occup Med Environ Health.* 2022;35(1):63-74. doi:10.13075/IJOMEH.1896.01826
40. Chadeau-Hyam M, Tang D, Eales O, et al. Omicron SARS-CoV-2 epidemic in England during February 2022: A series of cross-sectional community surveys. *The Lancet Regional Health - Europe.* 2022;21:200. doi:10.1016/j.lanepe.2022.100462

41. Shang Y, Liang Y, Liu T, Li J, Zhou F. Public screening for COVID-19 in Wuhan, China and beware of the antibody positive in women and tumor patients. *J Med Virol*. 2022;94(4):1535-1539. doi:10.1002/JMV.27483
42. Werneck GL, Porto LC, Sena A, et al. The incidence and geographical spread of SARS-CoV-2 in Rio de Janeiro, Brazil based on RT-PCR test results. *Rev Soc Bras Med Trop*. 2021;54(07792020):2021. doi:10.1590/0037-8682-0779-2020
43. Riley S, Ainslie KEC, Eales O, et al. Resurgence of SARS-CoV-2: Detection by community viral surveillance. *Science*. 2021;372(6545):990. doi:10.1126/SCIENCE.ABF0874
44. da Silva Torres MK, Lopes FT, de Lima ACR, et al. Seroprevalence and risk factors for COVID-19 in the metropolis of the Brazilian Amazon. *Sci Rep*. 2022;12(1). doi:10.1038/S41598-022-12629-Z
45. Elliott P, Bodinier B, Eales O, et al. Rapid increase in Omicron infections in England during December 2021: REACT-1 study. *Science*. 2022;375(6587):1406-1411. doi:10.1126/SCIENCE.ABN8347
46. Elliott P, Haw D, Wang H, et al. Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. *Science (1979)*. 2021;374(6574). doi:10.1126/SCIENCE.ABL9551/SUPPL_FILE/SCIENCE.ABL9551_MДАР_REPRODUCIBILITY_CHECKLIST.PDF
47. Chadeau-Hyam M, Wang H, Eales O, et al. SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys. *Lancet Respir Med*. 2022;10(4):355-366. doi:10.1016/S2213-2600(21)00542-7
48. Pillai J, Motloba P, Motaung K, et al. A descriptive analysis of the effect of the national COVID-19 lockdown on the workload and case mix of patients presenting to a district-level emergency

- centre in Cape Town, South Africa. *South African Medical Journal*. 2020;110(11):1113-1118.
doi:10.7196/SAMJ.2020.v110i11.15222
49. Alber D, Haidara FC, Luoma J, et al. Original research: SARS-CoV-2 infection and antibody seroprevalence in routine surveillance patients, healthcare workers and general population in Kita region, Mali: an observational study 2020–2021. *BMJ Open*. 2022;12(6):60367.
doi:10.1136/BMJOPEN-2021-060367
50. Cho SI, Kim YE, Jo SJ. Association of COVID-19 with skin diseases and relevant biologics: a cross-sectional study using nationwide claim data in South Korea. *British Journal of Dermatology*. 2021;184(2):296-303. doi:10.1111/BJD.19507
51. Fokam J, Takou D, Nka AD, et al. Epidemiological, virological and clinical features of SARS-CoV-2 among individuals during the first wave in Cameroon: Baseline analysis for the EDCTP PERFECT-Study RIA2020EF-3000. *J Public Health Afr*. 2022;13(1).
doi:10.4081/jphia.2022.2142
52. Jeewandara C, Guruge D, Abyrathna IS, et al. Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka. *Front Public Health*. 2021;9:724398.
doi:10.3389/FPUBH.2021.724398/BIBTEX
53. Sidhu SK, Singh K, Tuli AK, Bigdelitabar S, Jairath M. Prevalence of novel Corona Virus (severe acute respiratory syndrome Coronavirus 2) and its uncertain future in the different regions of Punjab. *Indian J Public Health*. 2022;66(1):45-48. doi:10.4103/IJPH.IJPH_1793_21
54. Chan PA, King E, Xu Y, et al. Seroprevalence of SARS-CoV-2 Antibodies in Rhode Island From a Statewide Random Sample. *Am J Public Health*. 2021;111(4):700.
doi:10.2105/AJPH.2020.306115

55. Goss CW, Maricque BB, Anwuri V V., et al. SARS-CoV-2 active infection prevalence and seroprevalence in the adult population of St. Louis County. *Ann Epidemiol.* 2022;71:31. doi:10.1016/J.ANNEPIDEM.2022.03.002
56. Merkely B, Szabó AJ, Kosztin A, et al. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. *Geroscience.* 2020;42(4):1063-1074. doi:10.1007/S11357-020-00226-9/TABLES/4
57. Bellizzi S, Alsawalha L, Sheikh Ali S, et al. A three-phase population based sero-epidemiological study: Assessing the trend in prevalence of SARS-CoV-2 during COVID-19 pandemic in Jordan. *One Health.* 2021;13. doi:10.1016/J.ONEHLT.2021.100292
58. Parrott JC, Annibale AM, Osahan S, et al. Prevalence of SARS-CoV-2 antibodies during phased access to vaccination: results from a population-based survey in New York City, September 2020–March 2021. *Epidemiol Infect.* 2022;150. doi:10.1017/S0950268822000875
59. Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. *Lancet Glob Health.* 2020;8(11):e1390-e1398. doi:10.1016/S2214-109X(20)30387-9
60. Aguilera X, González C, Apablaza M, et al. Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile. *Vaccines* 2022, Vol 10, Page 1002. 2022;10(7):1002. doi:10.3390/VACCINES10071002
61. Le Vu S, Jones G, Anna F, et al. Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance. *Nature Communications* 2021 12:1. 2021;12(1):1-7. doi:10.1038/s41467-021-23233-6

62. Selvavinayagam TS, Somasundaram A, Selvam JM, et al. Contribution of infection and vaccination to seroprevalence through two COVID waves in Tamil Nadu, India. *medRxiv*. Published online July 25, 2022:2021.11.14.21265758. doi:10.1101/2021.11.14.21265758
63. Metzger C, Leroy T, Bochnakian A, et al. Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic. *PLoS One*. 2023;18(4):e0269104. doi:10.1371/JOURNAL.PONE.0269104
64. Axfors C, Pezzullo AM, Contopoulos-Ioannidis DG, Apostolatos A, Ioannidis JPA. Differential COVID-19 infection rates in children, adults, and elderly: Systematic review and meta-analysis of 38 pre-vaccination national seroprevalence studies. *J Glob Health*. 2023;13:6004. doi:10.7189/JOGH.13.06004
65. Zhang J, Litvinova M, Liang Y, et al. Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. *Science (1979)*. 2020;368(6498):1481-1486. doi:10.1126/SCIENCE.ABB8001/SUPPL_FILE/PAPV2.PDF
66. Rumain B, Schneiderman M, Geliebter A. Prevalence of COVID-19 in adolescents and youth compared with older adults in states experiencing surges. *PLoS One*. 2021;16(3):e0242587. doi:10.1371/JOURNAL.PONE.0242587
67. Campos de Lima EE, Gayawan E, Baptista EA, Queiroz BL. Spatial pattern of COVID-19 deaths and infections in small areas of Brazil. *PLoS One*. 2021;16(2):e0246808. doi:10.1371/JOURNAL.PONE.0246808
68. Zhang Y, Wang Y, Ning G, He P, Wang W. Protecting older people: a high priority during the COVID-19 pandemic. *The Lancet*. 2022;400(10354):729-730. doi:10.1016/S0140-6736(22)01530-

69. Hale T, Angrist N, Goldszmidt R, et al. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). *Nature Human Behaviour* 2021 5:4. 2021;5(4):529-538. doi:10.1038/s41562-021-01079-8
70. Chen X, Chen Z, Azman AS, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. *Lancet Glob Health*. 2021;9(5):e598-e609. doi:10.1016/S2214-109X(21)00026-7/ATTACHMENT/61015D81-CEEE-42C5-ABD6-FCCEC02C875C/MMC2.PDF
71. Rostami A, Sepidarkish M, Fazlzadeh A, et al. Update on SARS-CoV-2 seroprevalence: regional and worldwide. *Clinical Microbiology and Infection*. 2021;27(12):1762-1771. doi:10.1016/j.cmi.2021.09.019
72. Byambasuren O, Dobler CC, Bell K, et al. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review. *PLoS One*. 2021;16(4). doi:10.1371/JOURNAL.PONE.0248946